The FDA approved Foundayo (orforglipron), a GLP-1-type peptide drug, on April 1, 2026, to help adults with obesity or overweight lose weight and keep it off when used with diet and exercise. The agency also cleared Awiqli (insulin icodec-abae), a long-acting insulin peptide, for blood sugar control in type 2 diabetes on March 26, 2026.

• •FDA approved Foundayo (orforglipron) on 4/1/2026 for obesity/overweight with comorbidity
• •Indication requires combination with reduced-calorie diet and increased physical activity
• •FDA also cleared Awiqli (insulin icodec-abae) on 3/26/2026 for type 2 diabetes glycemic control

The FDA proposed removing semaglutide, tirzepatide, and liraglutide (weight-loss and diabetes drugs) from the list of bulk ingredients that pharmacies can use to make cheaper compounded copies. The move would force patients to buy the brand-name versions instead of lower-cost pharmacy-made alternatives.

• •FDA proposes excluding semaglutide, tirzepatide, liraglutide from 503B bulks list
• •Federal Register notice dated 4/30/2026
• •Action targets bulk drug substances used by outsourcing facilities for compounding

Eli Lilly reported strong first-quarter 2026 earnings, with total revenue jumping 56% to $19.8 billion, driven largely by higher sales volume of its diabetes and weight-loss drugs Mounjaro and Zepbound. However, the company earned less money per dose sold due to lower prices for those two medicines.

• •Q1 2026 total revenue rose 56% to $19.8 billion
• •Growth driven by higher Mounjaro and Zepbound sales volume
• •Realized price per dose declined for both drugs